Profil
Richard Chesworth worked as Senior Vice President-Research at Epizyme, Inc. and as Chief Scientific Officer at Kymera Therapeutics, Inc. He holds a doctorate degree from the University of Oxford and an undergraduate degree from Imperial College London.
Anciens postes connus de Richard Chesworth
| Sociétés | Poste | Fin |
|---|---|---|
| KYMERA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 22/10/2021 |
| EPIZYME, INC. | Chief Tech/Sci/R&D Officer | - |
Formation de Richard Chesworth
| University of Oxford | Doctorate Degree |
| Imperial College London | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KYMERA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
